［1］KINSEY E,LEE HM.Management of hepatocellular carcinoma in 2024:The multidisciplinary paradigm in an evolving treatment landscape［J/OL］.Cancers（Basel),2024,16(3)(2024-02-04)［2024-02-10］.https://doi.org/10.3390/cancers16030666.
［2］CHAKRABORTY E,SARKAR D.Emerging therapies for hepatocellular carcinoma（HCC)［J］.Cancers（Basel),2022,14(11):2798.
［3］LLOVET M,DEBAERE T,KULIK L,et al.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma［J］.Nat Rev Gastroenterol Hepatol,2021,18(5):293-313.
［4］FRANCO-JUAREZ X,GONZALEZ-VILLASANA V,CAMACHO-MOLL E,et al.Mechanistic insights about sorafenib-,valproic acid-and metformin-induced cell death in hepatocellular carcinoma［J］.Int J Mol Sci,2024,25(3):1760.
［5］SANGRO B,SAROBE P,HERVAS-STUBBS S,et al.Advances in immunotherapy for hepatocellular carcinoma［J］.Nat Rev Gastroenterol Hepatol,2021,18(8):525-543.
［6］PALMER H,MALAGARI K,KULIK M.Role of locoregional therapies in the wake of systemic therapy［J］.J Hepatol,2020,72(2):277-287.
［7］JONES A,ISSA P,BAYLIN S.Targeting the cancer epigenome for therapy［J］.Nat Rev Genet,2016,17(10):630-641.
［8］ROUNDTREE A,EVANS E,PAN T,et al.Dynamic RNA modifications in gene expression regulation［J］.Cell,2017,169(7):1187-1200.
［9］SENDINC E,SHI Y.RNA m6A methylation across the transcriptome［J］.Mol Cell,2023,83(3):428-441.
［10］LIU T,WEI Q,JIN J,et al.The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation［J］.Nucleic Acids Res,2020,48(7):3816-3831.
［11］CHANG G,SHI L,YE Y,et al.YTHDF3 induces the translation of m(6)A-enriched gene transcripts to promote breast cancer brain metastasis［J］.Cancer Cell,2020,38(6):857-871.e7.
［12］CHEN H,PAN Y,ZHOU Q,et al.METTL3 inhibits antitumor immunity by targeting m(6)A-BHLHE41-CXCL1/CXCR2 axis to promote colorectal cancer［J］.Gastroenterology,2022,163(4):891-907.
［13］ZACCARA S,RIES RJ,JAFFREY R.Reading,writing and erasing mRNA methylation［J］.Nat Rev Mol Cell Biol,2019,20(10):608-624.
［14］OERUM S,MEYNIER V,CATALA M,et al.A comprehensive review of m6A/m6Am RNA methyltransferase structures［J］.Nucleic Acids Res,2021,49(13):7239-7255.
［15］LASMAN L,KRUPALNIK V,VIUKOV S,et al.Context-dependent functional compensation between YTHDF m6A reader proteins［J］.Genes Dev,2020,34(19-20):1373-1391.
［16］LIU J,GAO M,XU S,et al.YTHDF2/3 are required for somatic reprogramming through different RNA deadenylation pathways［J］.Cell Rep,2020,32(10):108120.
［17］ZACCARA S,JAFFREY R.A unified model for the function of YTHDF proteins in regulating m(6)A-modified mRNA［J］.Cell,2020,181(7):1582-1595.e18.
［18］WANG X,YUAN Z,LI Z,et al.Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma:Basic principles and recent advances［J］.Front Immunol,2024,15:1354313.
［19］LI L,WANG H.Heterogeneity of liver cancer and personalized therapy［J］.Cancer Lett,2016,379(2):191-197.
［20］姆尼热?阿卜力米提，谭遥，伊斯刊达尔?阿布力米提.肝细胞肝癌放射治疗研究进展［J］.现代肿瘤医学,2021,29(10):1817-1821.
MUNIRE?ABULIMITI,TAN Y,YISIKANDAER?ABULIMITI.Advances in radiotherapy for hepatocellular carcinoma［J］.Modern Oncology，2021,29(10):1817-1821.
［21］CHAN K,TSUI M,HO W,et al.Cellular heterogeneity and plasticity in liver cancer［J］.Semin Cancer Biol,2022,82:134-149.
［22］LIN Y,JIN X,NIE Q,et al.YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m(6)A-dependent manner［J］.Ann Transl Med,2022,10(2):83.
［23］DU H,ZOU NY,ZUO HL,et al.YTHDF3 mediates HNF1α regulation of cervical cancer radio-resistance by promoting RAD51D translation in an m6A-dependent manner［J］.Febs J,2023,290(7):1920-1935.
［24］ZHONG S,GUO Q,CHEN X,et al.The inhibition of YTHDF3/m(6)A/LRP6 reprograms fatty acid metabolism and suppresses lymph node metastasis in cervical cancer［J］.Int J Biol Sci,2024,20(3):916-936.
［25］YUAN D,CHEN J,HAO Q,et al.Methyltransferase-like 3 aggravates HCC development via mediating N6-methyladenosine of ubiquitin-specific protease 7［J］.J Oncol,2022,2022:6167832.
［26］HUANG A,YANG XR,CHUNG WY,et al.Targeted therapy for hepatocellular carcinoma［J］.Signal Transduct Target Ther,2020,5(1):146.
［27］LIU L,BORLAK J.Advances in liver cancer stem cell isolation and their characterization［J］.Stem Cell Rev Rep,2021,17(4):1215-1238.
［28］LEE TK,GUAN XY,MA S.Cancer stem cells in hepatocellular carcinoma-from origin to clinical implications［J］.Nat Rev Gastroenterol Hepatol,2022,19(1):26-44.
［29］MIRAGLIA S,GODFREY W,YIN AH,et al.A novel five transmembrane hematopoietic stem cell antigen:Isolation,characterization,and molecular cloning［J］.Blood,1997,90(12):5013-5021.
［30］YIN AH,MIRAGLIA S,ZANJANI D,et al.AC133,a novel marker for human hematopoietic stem and progenitor cells［J］.Blood,1997,90(12):5002-5012.
［31］MA S.Biology and clinical implications of CD133(+) liver cancer stem cells［J］.Exp Cell Res,2013,319(2):126-132.
［32］廖元宇，白玉贤.PD-1/PD-L1抑制剂治疗晚期肝细胞癌的机制及研究进展［J］.现代肿瘤医学，2021,29(11):1989－1993.
LIAO YY,BAI YX.The mechanism and research progress of PD-1/PD-L1 inhibitor in the treatment of advanced hepatocellular carcinoma［J］.Modern Oncology,2021,29(11):1989－1993.
［33］曹婷玉，时佳琪，郑桐森.PD-L1和sPD-L1作为肝癌免疫治疗标志物的研究进展［J］.现代肿瘤医学,2021,29(12):2177-2182.
CAO TY,SHI JQ,ZHENG TS.Research progress of PD-L1 and sPD-L1 as biomarkers of hepatocellular carcinoma immunotherapy［J］.Modern Oncology,2021,29(12):2177-2182.
［34］LI Q,HAN J,YANG Y,et al.PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy［J］.Front Immunol,2022,13:1070961.
［35］HAN R,LING C,WANG Y,et al.Enhancing HCC treatment:Innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition［J］.Cancer Cell Int,2023,23(1):203.
［36］YU Y,MENG LL,CHEN XY,et al.m(6)A reader YTHDF3 is associated with clinical prognosis,related RNA signatures and immunosuppression in gastric cancer［J］.Cell Signal,2023,108:110699.